Taken together, due to the critical oncogenic role of FBXO28 in ovarian cancer, our study indicated that targeting FBXO28 by its inhibitors could be a promising approach for the treatment of ovarian cancer. This evidence concerns the gene FBXO28 and ovarian cancer.